Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
Moodys
Cerilliant
Cantor Fitzgerald
Chubb
US Army
Baxter
QuintilesIMS
Federal Trade Commission

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,585,860

« Back to Dashboard

Summary for Patent: 7,585,860
Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:12/027,553
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,585,860

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-003 Nov 4, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,585,860

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 62 924Dec 24, 1999

Non-Orange Book US Patents Family Members for Patent 7,585,860

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,157,456 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
8,129,378 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
8,530,505 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
8,822,458 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
7,576,111 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
7,592,339 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,585,860

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 032436 ➤ Sign Up
Austria 289605 ➤ Sign Up
Australia 2004218729 ➤ Sign Up
Australia 2841401 ➤ Sign Up
Australia 775126 ➤ Sign Up
Bulgaria 106825 ➤ Sign Up
Bulgaria 65683 ➤ Sign Up
Brazil 0017050 ➤ Sign Up
Canada 2396561 ➤ Sign Up
China 100549008 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Deloitte
Teva
Express Scripts
Fuji
Argus Health
McKesson
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot